Cambridge Cognition Holdings plc (LON: COG), which develops and markets digital solutions to assess brain health, has today announced a brand new software product to assess mental health and wellbeing
Cambridge Cognition Holdings plc (LON:COG), the digital neuroscience company Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce a
We’re delighted to announce a new $0.5m contract with a major pharmaceutical company for the use of our Cognition Kit digital health software in a clinical trial. Cognition Kit measures
The results of the 2018 CANTAB Research Grant are in! Once again we were overwhelmed by the quality of applications we received – which made it a tough job for our judging
Dr Steven Powell, Chief Executive Officer, at Cambridge Cognition said: “The pharmaceutical industry is increasingly looking to develop novel biomarkers and use digital phenotyping techniques to improve their data intelligence
The neuroscience digital health company Cambridge Cognition Holdings PLC (Cambridge, UK – LSE: COG), which develops and markets software products to improve brain health, today confirmed that the Annual Report and
The digital neuroscience company Cambridge Cognition Holdings plc, (LON:COG), which develops and markets software products to assess brain health, has today announced that its CANTAB Recruit software is now established in
Dr. Steven Powell, Chief Executive Officer, at Cambridge Cognition said: “We are delighted to have been awarded this substantial clinical contract by our pharmaceutical partner to work with them to
Cambridge Cognition’s Dr Steven Powell discusses their full year results for the year ended 31st December 2017 in this exclusive interview with DirectorsTalk
Cambridge Cognition Holdings plc (LON:COG), the neuroscience digital health company specialising in improving brain health by developing & marketing near-patient cognitive testing technologies for pharmaceutical and healthcare industries worldwide, today
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
